A Phase 1, Dose-Finding Study of Folotyn (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With Peripheral T-Cell Lymphoma (PTCL)

Trial Profile

A Phase 1, Dose-Finding Study of Folotyn (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With Peripheral T-Cell Lymphoma (PTCL)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Dec 2017

At a glance

  • Drugs Pralatrexate (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Peripheral T-cell lymphoma
  • Focus Adverse reactions
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 13 Dec 2017 According to a Spectrum Pharmaceuticals Media Release, data from this trial were presented at the 59th American Society of Hematology (ASH).
    • 13 Dec 2017 Results published in the Spectrum Pharmaceuticals Media Release.
    • 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top